On 28 June 2022, Basilea announced positive top-line results from the Phase III ERADICATE study, investigating the use of its drug-resistant antibacterial agent, Zevtera (ceftobiprole) in the treatment of Staphylococcus aureus bacteraemia (SAB). In combination with the 2019 Phase III TARGET study in acute bacterial skin and skin structure infections (ABSSSI), the results complete the data package for Basilea to seek FDA approval for Zevtera in both indications. Management expects to file a new d ....
01 Jul 2022
Basilea Pharmaceutica - Zevtera path to US approval open
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - Zevtera path to US approval open
On 28 June 2022, Basilea announced positive top-line results from the Phase III ERADICATE study, investigating the use of its drug-resistant antibacterial agent, Zevtera (ceftobiprole) in the treatment of Staphylococcus aureus bacteraemia (SAB). In combination with the 2019 Phase III TARGET study in acute bacterial skin and skin structure infections (ABSSSI), the results complete the data package for Basilea to seek FDA approval for Zevtera in both indications. Management expects to file a new d ....